36.25 Gy/5 showed similar five-year control to 40 Gy/5 in prostate SBRT
After propensity matching, five-year PSA recurrence-free survival was 94.5% with 36.25 Gy versus 93.2% with 40 Gy.
Tag
prostate
National audit-driven changes halved severe late GI toxicity after prostate radiotherapy
After a national audit triggered pathway redesign, severe late GI toxicity after prostate EBRT fell from 16% to 7.5%.
Overfilling the bladder made prostate radiotherapy longer and more frustrating
Bladder diameter >10 cm at simulation was associated with longer fractions, more interruptions and greater patient frustration during prostate RT.
Two salvage HDR brachytherapy schedules produced similar outcomes in recurrent prostate cancer
In 223 previously irradiated patients, 3×10 Gy and 2×13 Gy salvage HDR brachytherapy produced similar disease control and late toxicity.
Deep learning could provide a second-check for prostate pelvic nodal contours
AI pelvic nodal contours achieved a Dice score of 0.79 on withheld prostate RT cases but retained localized boundary disagreements.
Metastasis-directed EBRT was feasible alongside Lu-PSMA-617 in metastatic prostate cancer
Among 88 patients receiving both treatments, PSA50 response was 55.7% and prior metastasis-directed EBRT did not increase hematologic toxicity.
PET-directed nodal RT plus temporary ADT showed durable 10-year prostate cancer outcomes
PET-directed elective nodal RT plus temporary ADT yielded 77% 10-year overall survival with low grade 3 GU and GI toxicity.
PSMA/MRI-guided prostate SABR with focal boost showed strong two-year imaging response
In ARGOS-CLIMBER, PSMA/MRI-guided five-fraction pelvic SABR produced a 67% PET complete response rate at two years with limited late GU toxicity.
Clinicians underestimated urinary and bowel symptoms after prostate radiotherapy
HYPO-RT-PC showed persistently poor agreement between patient- and clinician-reported toxicity, particularly for urinary and bowel symptoms.
MR-guided prostate re-irradiation achieved high early control but accumulating GU toxicity
Failure-free survival was 96.6% at 12 months, while grade 3 GU toxicity increased to 12.5% by one year.
FDVH-guided re-optimization improved RapidPlan prostate VMAT plans
Patient-specific feasibility guidance improved target homogeneity and reduced rectal low-dose exposure after automated RapidPlan optimization.
Single-arc VMAT remained comparable to double-arc planning with bilateral hip prostheses
Double-arc VMAT was slightly more robust, but single-arc planning achieved clinically comparable dosimetry with simulated bilateral hip prostheses.
Salvage proton therapy achieved durable control after prostate cryotherapy or HIFU failure
Ten-year biochemical control was 64.7% after salvage proton therapy, with 3.2% late grade 3 genitourinary toxicity.
Dose-escalated prostate SBRT was associated with worse late urinary quality of life
Late urinary worsening occurred in 80% after >40 Gy prostate SBRT versus 68% after ≤40 Gy, while bowel outcomes remained similar.
Daily MR-guided salvage radiotherapy showed low severe toxicity after prostatectomy
Daily adaptive salvage radiotherapy produced 6% new grade ≥2 urinary toxicity at 12 months in a prospective 51-patient cohort.